Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment

BERLIN, Sept. 25, 2019 /PRNewswire/ -- Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round involves...

from PR Newswire: https://ift.tt/2mB5xSw